• Facing
    Metastatic Cancer
    • Is Metastatic Cancer Curable?
    • Access to the Right Treatment
    • Registering with Cancer Commons
    • Enroll in XCELSIOR
    • Can a Virtual Tumor Board Help?
    • Get Help With Your Treatment Plan
  • New Cancer Research
    & Perspectives
    • Bladder Cancer
    • Brain Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Diffuse Midline Glioma
    • Esophageal Cancer
    • Kidney Cancer
    • Leukemia
    • Liver Cancer
    • Lung Cancer
    • Lymphoma
    • Melanoma
    • Ovarian Cancer
    • Pancreatic Cancer
    • Prostate Cancer
    • Uterine Cancer
  • Our Story
    • It Started in 1998…
    • We’re Here to Help
    • Why We Go to Work Each Day
    • Our Services
    • Meet the Team
    • Why we built a “Commons”
    • Our Partners
    • Keeping Our Services Free
    • Talk to Us
  • Support Our
    Free Services
    • Donate Now
    • Many Ways to Give
    • Funding Initiatives
    • What Your Support Makes Possible
  • Facing
    Metastatic Cancer
    • Is Metastatic Cancer Curable?
    • Access to the Right Treatment
    • Registering with Cancer Commons
    • Enroll in XCELSIOR
    • Can a Virtual Tumor Board Help?
    • Get Help With Your Treatment Plan
  • New Cancer Research
    & Perspectives
    • Bladder Cancer
    • Brain Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Diffuse Midline Glioma
    • Esophageal Cancer
    • Kidney Cancer
    • Leukemia
    • Liver Cancer
    • Lung Cancer
    • Lymphoma
    • Melanoma
    • Ovarian Cancer
    • Pancreatic Cancer
    • Prostate Cancer
    • Uterine Cancer
  • Our Story
    • It Started in 1998…
    • We’re Here to Help
    • Why We Go to Work Each Day
    • Our Services
    • Meet the Team
    • Why we built a “Commons”
    • Our Partners
    • Keeping Our Services Free
    • Talk to Us
  • Support Our
    Free Services
    • Donate Now
    • Many Ways to Give
    • Funding Initiatives
    • What Your Support Makes Possible
  • Donate
 

Treatment Options

Learn about the latest treatments for advanced cancer. We’ve got it covered, from new FDA approvals to emerging approaches in immunotherapy, targeted therapy, cancer vaccines, modified viruses, and more.

  • February 22, 2020 

    ‘Unprecedented’ Responses to Cisplatin/Gemcitabine in BRCA-Mutated Advanced Pancreatic CancerBookmark

    George Lundberg, MD

    Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

    A treatment that combines two drugs can be beneficial for some patients who have advanced pancreatic cancer with BRCA mutations.

    Go to full article published by The ASCO Post.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • February 22, 2020 

    Data Favor Max Resection for All GlioblastomasBookmark

    George Lundberg, MD

    Article from MedPage Today curated by Editor in Chief George Lundberg, MD, who notes: 

    A large, retrospective study demonstrates that surgical removal of as much tumor tissue as possible results in the best outcomes for patients—seems pretty logical, and is true.

    Go to full article published by MedPage Today.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • January 31, 2020 

    FDA Grants Priority Review to Olaparib, Bevacizumab Combination for Ovarian CancerBookmark

    George Lundberg, MD

    Article from Cancer Network curated by Editor in Chief George Lundberg, MD, who notes: 

    In precision oncology, drugs combinations may provide new effective treatment.

    Go to full article published by Cancer Network.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • January 10, 2020 

    Using Real World Evidence to Show Initial Results of a Drug Combination in Pancreatic Cancer Patients

    Lola Rahib, PhD

    In collaboration with xCures and the Huntsman Cancer Institute at the University of Utah, Cancer Commons presented initial findings from our real-world data registry on a novel treatment combination for pancreatic cancer patients at a conference in San Diego, CA, today. The “Special Conference on Advancing Precision Advancing Precision Medicine Drug Development: Incorporation of Real-World Data and Other Novel Strategies” is hosted by the… Read more »

  • January 7, 2020 

    FDA Approves Lynparza as First-Line Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic CancerBookmark

    George Lundberg, MD

    Article from The Cancer Letter curated by Editor in Chief George Lundberg, MD, who notes: 

    The U.S. Food and Drug Administration (FDA) has approved olaparib (Lynparza) for marketing and sales for a narrow group of metastatic pancreatic cancer patients, based on rates of progression-free survival in a clinical trial published in The New England Journal of Medicine.

    Go to full article published by The Cancer Letter.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • December 26, 2019 

    Pembrolizumab Approved for Some Patients with Advanced Esophageal CancerBookmark

    George Lundberg, MD

    Article from the National Cancer Institute curated by Editor in Chief George Lundberg, MD, who notes: 

    In 2019, the U.S. Food and Drug Administration (FDA) approved pembrolizumab for certain advanced esophageal cancers, depending on testing results. The National Cancer Institute explains here.

    Go to full article published by the National Cancer Institute.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • December 23, 2019 

    Renal Cell Cancer Treatment: The Old, the Almost Old, and the New

    Emma Shtivelman, PhD

    Clear cell renal cell cancer (ccRCC) is the predominant type of kidney cancer, accounting for 70% to 75% of all kidney cancers. Here, I outline the current treatment landscape for ccRCC, highlighting what’s new and what’s on the horizon. Surgical removal of the cancerous kidney is most often the first treatment after diagnosis, especially if the tumors exceed 3- to 4 cm in size.… Read more »

  • December 13, 2019 

    New Standard of Care for Metastatic Renal Cell CarcinomaBookmark

    George Lundberg, MD

    Article from Medscape curated by Editor in Chief George Lundberg, MD, who notes: 

    This piece describes huge improvements in the standard of care and outcomes from combo therapy in metastatic renal cell carcinoma.

    Go to full article published by Medscape.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • December 13, 2019 

    Plasmacytoid Urothelial Carcinoma: An Unusual Variant That Warrants Aggressive Management and Critical Distinction on Transurethral ResectionsBookmark

    George Lundberg, MD

    Research paper from the Archives of Pathology & Laboratory Medicine curated by Editor in Chief George Lundberg, MD, who notes: 

    Plasmacytoid urothelial carcinoma merits special aggressive therapy.

    Go to full paper published in the Archives of Pathology & Laboratory Medicine.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • December 2, 2019 

    Secondary Surgical Cytoreduction Plus Chemotherapy vs Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian CancerBookmark

    George Lundberg, MD

    Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

    Chemotherapy alone bests cytoreductive surgery plus chemotherapy in recurrent ovarian cancer.

    Go to full article published by The ASCO Post.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

    • «
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • …
    • 20
    • »

Dr. Rahib is extremely helpful and I am very thankful to have access to such professional and state-of-the-art support.

Ines
Daughter of pancreatic cancer patient


You can makea differenceDonate

Precision oncology is very complicated and changes every day. The scientists of Cancer Commons provide rapid, compassionate, scientifically sound information about best options, a remarkable free service.

Razelle Kurzrock, MD
U.C. San Diego, CureMatch, Inc.

Cancer Commons is a nonprofit that provides hope to advanced cancer patients by helping them identify and access their best possible treatment. We offer a highly customized experience, connecting patients with our collaborative network of nurse navigators, PhD scientists, and national experts. We learn from every patient we serve, so we can help many more.

Don't miss Cancer Commons Connects
Exclusive monthly insights and stories—from and for our community

Working.

Get free advice on cancer treatment options

Patient Services

  • Get Access to the Right Treatment
  • Request an Options Report
  • Frequently Asked Questions (FAQ)

Perspectives

  • Latest Research & Perspectives
  • Treatment Options
  • Navigating Treatment
  • Living with Cancer
  • Patient Stories
  • Curious Dr. George
  • The Big Picture
  • COVID-19 and Cancer
  • Peer-Reviewed Publications

Organization

  • Our Story
  • The Team
  • Board of Directors
  • Advisory Board
  • The Commons
  • Partners
  • Expert Physician Advisors
  • Open Positions

Corporate & Regulatory

  • News and Events
  • Funding Initiatives
  • Contact Us
  • Cancer Commons International
  • Reports and Financials

Support & Giving

  • Donate
  • Other Ways to Give
  • Funding Initiatives
  • What Your Support Makes Possible
  • Testimonials


Donate

Cancer Commons
650 Castro Street, Suite 120-522
Mountain View, CA 94041, USA
650-289-4044

Patients Hotline

877-971-1200

If you have advanced or metastatic cancer, and you are a U.S. resident, our experts are here to help you identify the best-possible treatment options—all at no cost to you. Our one-on-one support is driven by the latest, evidence-based scientific discoveries.

To get started, simply fill out this form. You will then receive an email with a link to submit additional information.

  • Privacy Policy

© 2021 Cancer Commons.